Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F8DL
|
|||
| Former ID |
DNC001280
|
|||
| Drug Name |
SB 203580
|
|||
| Synonyms |
152121-47-6; SB-203580; SB203580; 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1H-imidazol-5-yl)pyridine; 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole; CHEBI:90705; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; CHEMBL10; RWJ 64809; 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine; PB 203580; UNII-WS78QR6DSV
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H16FN3OS
|
|||
| Canonical SMILES |
CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
|
|||
| InChIKey |
CDMGBJANTYXAIV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 152121-47-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
794099, 3727017, 4881696, 7885391, 7980717, 11113952, 11113953, 11120137, 11120625, 11121113, 11147220, 11548420, 14720324, 14779945, 14804412, 24899788, 26752101, 26759478, 26759483, 33499832, 46391337, 46392883, 46513744, 48110703, 49684193, 50070516, 50071154, 50100115, 50104755, 53788760, 56310897, 56311795, 57395287, 80363426, 84943990, 85787285, 87363401, 92310088, 99217496, 99301000, 99302824, 99374146, 99437224, 103163913, 103904989, 104425365, 109693171, 124756980, 124886984, 125163785
|
|||
| ChEBI ID |
CHEBI:90705
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001 Jun;187(3):294-303. | |||
| REF 2 | Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185-201. | |||
| REF 3 | The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73. | |||
| REF 4 | Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.